Concepedia

Mark T. Kershaw

MT

10

Publications

408

Citations

10

H-Index

2002

Active since

Affiliations

Forma Therapeutics (United States)(Current)

Repligen (United States)

Mark T. Kershaw is an author at Forma Therapeutics (United States) specializing in drug discovery, medicine, and pharmacology.

Top concepts

Publications per year

2002–2020

10

Publications

10

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor

Justin A. Caravella, Jian Lin, R. Bruce Diebold et al. · Journal of Medicinal Chemistry · 2020 · 132 citations · Full text

Ethyl 2-Chlorooxazole-4-carboxylate:  A Versatile Intermediate for the Synthesis of Substituted Oxazoles

Kevin J. Hodgetts, Mark T. Kershaw · Organic Letters · 2002 · 62 citations

, , +12

Regiocontrolled Synthesis of Substituted Thiazoles

Kevin J. Hodgetts, Mark T. Kershaw · Organic Letters · 2002 · 48 citations

, , +9

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors

Jian Lin, Wei Lu, Justin A. Caravella et al. · Journal of Medicinal Chemistry · 2019 · 46 citations · Full text

Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists

Charles A. Blum, Timothy M. Caldwell, Xiaozhang Zheng et al. · Journal of Medicinal Chemistry · 2010 · 37 citations · Full text

, , +16

Rows per page

1–5 of 10